Safety, Tolerability, and Antihypertensive Effect of SER100, an Opiate Receptor‐Like 1 (ORL‐1) Partial Agonist, in Patients With Isolated Systolic Hypertension. Issue 6 (29th December 2016)

• Record Type: Journal Article
• Authors: Kantola, Ilkka; Scheinin, Mika; Gulbrandsen, Trygve; Meland, Nils; Smerud, Knut T.
• Is Part Of: Clinical pharmacology in drug development. Volume 6:Issue 6(2017)
• Page Start: 584
• Page End: 591
• Publication Date: 2016-12-29
• Subjects: crossover -- isolated systolic hypertension -- NOP partial agonist -- ORL‐1 agonist -- OP4 -- placebo‐controlled randomized clinical trial -- SER100; Drugs -- Testing -- Periodicals; Drug development -- Periodicals; Clinical pharmacology -- Periodicals; 615.580724
• DOI: 10.1002/cpdd.330
• Languages: English
• ISSNs: 2160-7648

Abstract

Abstract: The purpose of the present trial was to evaluate safety, tolerability, and effect on systolic blood pressure (SBP) of SER100 in a small group of patients with isolated systolic hypertension (ISH) in treatment with at least 1 antihypertensive drug. Eligible patients were randomized to either SER100 (10 mg) or placebo in a crossover design, and 2 doses were given subcutaneously (SC), 8 hours apart, on 2 consecutive days. On all treatment days patients were monitored with an ambulatory blood pressure measurement device for 12 daytime hours. Seventeen patients completed treatment. There were no serious or severe adverse events. Relative to placebo SER100 induced an average reduction of SBP during the 2 treatment days of 7.0 mm Hg ( P = 0.0032), whereas the average reduction of diastolic blood pressure (DBP) over the same period was 3.8 mm Hg ( P = 0.0011). For patients with ISH, this short‐term cross‐over study of SC SER100 demonstrated an acceptable safety profile and consistent, significant lowering of SBP and DBP. As initial clinical proof of concept for a new class of drugs, a nociceptin agonist peptide, the results were encouraging and warrant further research.